Physician profile
Danielle Doyle
NPI 1063647998
$1,517.29
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $244 · 2021: $679 · 2022: $262 · 2024: $27.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $521.33 | 2019-2022 | |
| Abbott Laboratories | $113.77 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $94.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.34 | 2022 | |
| Abbvie INC. | $71.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $71.05 | 2019 | |
| Pfizer INC. | $69.60 | 2019-2021 | |
| Almatica Pharma LLC | $68.69 | 2021 | |
| Scilex Pharmaceuticals INC. | $60.21 | 2019-2020 | |
| Boston Scientific Corporation | $58.21 | 2019-2021 | |
| Nevro Corp. | $53.02 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $46.05 | 2021 | |
| Lilly USA, LLC | $45.09 | 2021-2024 | Omvoh |
| Hikma Pharmaceuticals USA | $42.00 | 2022 | |
| Arbor Pharmaceuticals, INC. | $28.65 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $26.58 | 2020 | |
| Avanos Medical | $21.51 | 2021 | |
| Amgen INC. | $19.15 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.53 | 2022 | |
| Stratus Medical, LLC | $11.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.